Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 1, 2013

BioPharm International

  • BioPharm International-09-01-2013
  • Volume 26
  • Issue 9

Ion Exchange Chromatography Resins for High-Resolution Purification

Tosoh Bioscience's two ion exchange chromatography resins are designed for the high-resolution purification of proteins, peptides, and oligonucleotides.

Tosoh Bioscience’s two ion exchange chromatography resins are designed for the high-resolution purification of proteins, peptides, and oligonucleotides.

TOYOPEARL GigaCap S-grade resins maintain the high capacity of Tosoh Bioscience’s TOYOPEARLGigaCap M-grade resins while the S-grade’s 35 μm particle size provides high resolution for improved separation of process impurities and aggregates.

The TOYOPEARL GigaCap Q-650S anion exchange resin meets the growing demand for higher resolution process chromatography products and is suitable for applications from the capture of oligonucleotides to the polishing of monoclonal antibodies. The TOYOPEARL GigaCap S-650S cation exchange resin has been optimized for the high resolution purification of IgGs, peptides, and monoclonal antibodies.

Tosoh Bioscience

 

Articles in this issue


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.